Pain Management

Suzetrigine, the investigational selective NaV1.8 pain signal inhibitor, with a PDUFA date of Jan 30, could become a first-in-class nonopioid analgesic.

NX-102 SL is a non-opioid, centrally acting analgesic, granted Fast Track designation by FDA.

Pain relief with suzetrigine was comparable to that seen with placebo, an issue Vertex plans to address with study design as the drug moves to the pivotal phase 3 trials.

If approved, the nonopioid, centrally acting analgesic would be the first in a new class of medications for fibromyalgia in more than 15 years, Tonix said.

The efficacy of acupuncture treatment for chronic pain is still widely debated. A new study evaluated its effect on one of the most treatment resistant forms of low back pain.

Findings from a recent review highlight the impact of common analgesic medications on sleep patterns in people with chronic pain.

The FDA has set a PDUFA date of January 30, 2025 for the investigational oral nonopioid therapy for acute pain, which could be a first-in-class win for Vertex.

Your daily dose of the clinical news you may have missed.

Findings from a systematic review and meta-analysis showed 1 in 3 youth with chronic pain were diagnosed with anxiety and 1 in 8 were diagnosed with depression.

One in 9 primary care encounters involved a mental health condition, according to an analysis of over 350 million primary care visits.

If approved the selective NaV1.8 pain signal inhibitor would reflect the first new class of pain management medication in more than 20 years.

Get details on the relationship between obesity and mental health conditions, chronic pain, and hypertension, here.

A clinician's empathy during a clinic encounter with a person with chronic pain can have a statistically significant impact on outcomes, a new study found.

Patient is in his forties; pain has been waxing, waning, worsening for 2 weeks. He has no other significant medical history. Do lab results hold clues? What's your Dx?

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Atogepant was associated with fewer monthly migraine days, fewer acute medication use days, and greater QoL compared with rimegepant after 12 weeks.

A new study compared opioid utilization trajectories of patients initiating tramadol, hydrocodone, and oxycodone. Key takeaways at-a-glance, here.

Your daily dose of the clinical news you may have missed.

Oral VX-548 has the potential to fill the gap between drugs that are tolerable but lack efficacy and opioids with therapeutic efficacy but known risks, according to Vertex.

Your daily dose of the clinical news you may have missed.

Gabapentinoid use increased from 4.0% of the population reporting use of the medication in 2015 to 4.7% in 2021, according to new data.

In persons with COPD, use of the anticonvulsants was linked to a 39% increase in risk of severe disease exacerbation requiring hospital admission, study authors reported.

A recent review analyzed the effectiveness of nonpharmacologic therapies for neuropathic pain in older adults. Results in our new slide show.

Knee pain is the presenting symptom for ~5% of primary care visits. Following are highlight of a JAMA review covering the 3 most common etiologies.